ClinicaliQ Trial Snapshot
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) — Active Not Recruiting • Phase II • Respiratory / COPD / Asthma • NCT05270668.
- A study testing a new drug (tulisokibart) to treat scleroderma patients with lung scarring to see if it's safe and effective.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD. Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease Interventions: Tulisokibart, Companion diagnostic ( CDx), Placebo Lead Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Planned Enrollment: 154 participants